Skip to main content

Table 1 Prevalence of poor prognostic factors at baseline in ORAL Scan and ORAL Start

From: Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials

  ORAL Scan ORAL Start
(N = 720) (N = 880)
Patients with poor prognostic factor, n/N (%)
 CCP+ 600/718 (83.6) 737/880 (83.8)
 DAS28-4(ESR) >5.1 635/715 (88.8) 822/879 (93.5)
 RF+ 546/718 (76.0) 726/880 (82.5)
 CRP+ (>7 mg/L) 416/720 (57.8) 592/880 (67.3)
 Erosion score ≥3 460/720 (63.9) 403/880 (45.8)
 Baseline mTSS > mediana 360/720 (50.0) 433/880 (49.2)
Number of poor prognostic factors present at baseline, n/N (%)
  ≥ 1 719/720 (99.9) 878/880 (99.8)
  ≥ 2 689/720 (95.7) 847/880 (96.3)
  ≥ 3 627/720 (87.1) 780/880 (88.6)
  ≥ 4 504/720 (70.0) 625/880 (71.0)
  ≥ 5 315/720 (43.8) 368/880 (41.8)
 6 163/720 (22.6) 215/880 (24.4)
  1. There were two patients in the ORAL Scan study and two patients in the ORAL Start study who had no poor prognostic factors at baseline
  2. CCP cyclic citrullinated peptide, CRP C-reactive protein, DAS28-4(ESR) Disease Activity Score in 28 joints (erythrocyte sedimentation rate), mTSS van der Heijde modified total Sharp score, RF rheumatoid factor
  3. aMedian baseline mTSS value was 13.1 for ORAL Scan and 4.0 for ORAL Start